Eagye Kathryn J, Kuti Joseph L, Nicolau David P
Center for Anti-Infective Research and Development, Hartford Hospital, CT 06102, USA.
Infect Control Hosp Epidemiol. 2009 Aug;30(8):746-52. doi: 10.1086/603527.
To determine risk factors and outcomes for patients with meropenem high-level-resistant Pseudomonas aeruginosa (MRPA) (minimum inhibitory concentration [MIC] > or = 32 microg/mL).
Case-control-control.
An 867-bed urban, teaching hospital.
Fifty-eight MRPA case patients identified from an earlier P. aeruginosa study; 125 randomly selected control patients with meropenem-susceptible P. aeruginosa (MSPA) (MIC < or = 4 microg/mL), and 57 control patients without P. aeruginosa (sampled by case date/location).
Patient data, outcomes, and costs were obtained via administrative database. Cases were compared to each control group while controlling for time at risk (days between admission and culture, or entire length of stay [LOS] for patients without P. aeruginosa).
A multivariable model predicted risks for MRPA versus MSPA (odds ratio [95% confidence interval]): more admissions (in the prior 12 months) (1.41 [1.15, 1.74]), congestive heart failure (2.19 [1.03, 4.68]), and Foley catheter (2.53 [1.18, 5.45]) (adj. R(2) = 0.28). For MRPA versus no P. aeruginosa, risks were age (in 5-year increments) (1.17 [1.03, 1.33]), more prior admissions (1.40 [1.08, 1.81]), and more days in the intensive care unit (1.10 [1.03, 1.18]) (adj. R(2) = 0.32). Other invasive devices (including mechanical ventilation) and previous antibiotic use (including carbapenems) were nonsignificant. MRPA mortality (31%) did not differ from that of MSPA (15%) when adjusted for time at risk (P = .15) but did from mortality without P. aeruginosa (9%) (P = .01). Median LOS and costs were greater for MRPA patients versus MSPA patients and patients without P. aeruginosa: 30 days versus 16 and 10 (P<.01) and $88,425 versus $28,620 and $22,605 (P<.01).
Although antibiotic use has been shown to promote resistance, our data found that prior antibiotic use was not associated with MRPA acquisition. However, admission frequency and Foley catheters were, suggesting that infection control measures are essential to reducing MRPA transmission.
确定美罗培南高水平耐药铜绿假单胞菌(MRPA)(最低抑菌浓度[MIC]≥32μg/mL)患者的危险因素及预后情况。
病例对照 - 对照研究。
一家拥有867张床位的城市教学医院。
从早期铜绿假单胞菌研究中确定的58例MRPA病例患者;125例随机选取的对美罗培南敏感的铜绿假单胞菌(MSPA)(MIC≤4μg/mL)对照患者,以及57例无铜绿假单胞菌的对照患者(按病例日期/地点抽样)。
通过行政数据库获取患者数据、预后情况及费用。在控制风险时间(入院至培养之间的天数,或无铜绿假单胞菌患者的整个住院时长[LOS])的情况下,将病例与每个对照组进行比较。
多变量模型预测了MRPA与MSPA相比的风险(比值比[95%置信区间]):更多的入院次数(在过去12个月内)(1.41[1.15, 1.74])、充血性心力衰竭(2.19[1.03, 4.68])以及留置导尿管(2.53[1.18, 5.45])(调整后R² = 0.28)。对于MRPA与无铜绿假单胞菌患者相比,风险因素为年龄(以5岁为增量)(1.17[1.03, 1.33])、更多的既往入院次数(1.40[1.08, 1.81])以及在重症监护病房的天数更多(1.10[1.03, 1.18])(调整后R² = 0.32)。其他侵入性设备(包括机械通气)和既往抗生素使用(包括碳青霉烯类)无显著意义。调整风险时间后,MRPA的死亡率(31%)与MSPA的死亡率(15%)无差异(P = 0.15),但与无铜绿假单胞菌患者的死亡率(9%)有差异(P = 0.01)。MRPA患者的中位LOS和费用高于MSPA患者以及无铜绿假单胞菌患者:分别为30天、16天和10天(P<0.01),以及88,425美元、28,620美元和22,605美元(P<0.01)。
尽管已证明抗生素使用会促进耐药性产生,但我们的数据发现既往抗生素使用与MRPA感染无关。然而,入院频率和留置导尿管与之相关,这表明感染控制措施对于减少MRPA传播至关重要。